News

The company said that EVZIO is not a substitute for emergency medical care and it is approved by the US Food and Drug Administration (FDA) in April 2014.

The Geo Well Fermentation facility (GWF) is an underground earth-vessel based technology that will produce microbial products with a number of advantages. Primarily, the capital investment involved is

This follows the previously disclosed proteins already scheduled for production at PBP, namely plasminogen, IVIG and Alpha-1 Antitrypsin. Sales of fibrinogen manufactured at commercial scale to pharmaceutical companies

The application includes composition of matter claims on broad families of melanocortin receptor-1 specific peptides with potential utility for treatment of inflammatory diseases and disorders. The melanocortin-1 receptor

Numerous challenges limit the pace of progress for global clinical research. According to ACRES, the industry squanders $20 billion annually due to inefficiencies inherent to the current process

The expansion into aesthetic and corrective dermatology in the U.S. and Canada completes Galderma’s global skin health footprint and extends its leadership in aesthetic medicine worldwide. "We at

The move follows BMS’ discussions with FDA and will mark the second tumor type for which the company has a regulatory submission underway for Opdivo in the US.

The company said that ATX-101 NDA, which was submitted in May 2014, will be subject to a standard review and will have a Prescription Drug User Fee Act

Treatment for advanced ovarian carcinoma is typically based on the combination of surgery and chemotherapy. The objective of surgical intervention in patients suffering from advanced disease is to